XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Jun. 16, 2021
USD ($)
Dec. 31, 2023
USD ($)
Segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Accounting Policy [Line Items]        
Number of operating segment | Segment   1    
Highly liquid investment maturity period   three months or less    
Restricted time deposits   $ 1,700,000 $ 2,100,000  
Cash and cash equivalents   $ 113,688,000 155,700,000  
Short term investments maturity   12 months    
Long term Investments Maturity   12 months    
Impairment of long-lived assets   $ 0 0  
Impairment of inatangible assets finite lived   $ 0 0 $ 0
Description of payment term   The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.    
Description of sales return   distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.    
Accumulated deficit   $ (1,841,920,000) (1,557,688,000)  
Accumulated other comprehensive loss   $ (6,875,000) (5,720,000)  
AstraZeneca Agreements [Member]        
Accounting Policy [Line Items]        
Profit share percent   50.00%    
HiFiBiO Agreement [Member]        
Accounting Policy [Line Items]        
Initial upfront payment $ 25,000,000.0      
Maximum R&D and regulatory milestone payments receivable   $ 175,000,000    
Maximum sales milestones receivable   $ 170,000,000    
Percentage of tiered royalties receivable   10.00%    
HiFiBiO Agreement [Member] | IPR&D Asset [Member]        
Accounting Policy [Line Items]        
Initial upfront payment       60,000,000.0
HiFiBiO Agreement [Member] | Accrued Liabilities        
Accounting Policy [Line Items]        
Initial upfront payment       $ 35,000,000.0
Minimum [Member] | Computer Equipment [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   3 years    
Minimum [Member] | Laboratory Equipment [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   3 years    
Minimum [Member] | Machinery [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   3 years    
Minimum [Member] | Furniture and Fixtures [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   3 years    
Maximum [Member] | Computer Equipment [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   5 years    
Maximum [Member] | Laboratory Equipment [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   5 years    
Maximum [Member] | Machinery [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   5 years    
Maximum [Member] | Furniture and Fixtures [Member]        
Accounting Policy [Line Items]        
Property and equipment estimated useful life   5 years    
Foreign subsidiaries [Member]        
Accounting Policy [Line Items]        
Cash and cash equivalents   $ 32,200,000 $ 92,500,000  
Accounts Receivable from Distributors [Member] | Credit Concentration Risk [Member] | Roxadustat [Member]        
Accounting Policy [Line Items]        
Concentration risk, percentage   17.00% 10.00%